VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ECCO 2017 | Developments in Hodgkin lymphoma, CLL, multiple myeloma and follicular lymphoma

Franco Cavalli, MD, FRCP from the Oncology Institute of Southern Switzerland, Bellinzona, Switzerland gives an overview of developments in Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and follicular lymphoma. Prof. Cavali explains the remaining challenges in Hodgkin lymphoma, including using PET-guided treatment. In CLL, the main message is that we are close to developing a curative treatment. In multiple myeloma, the main question is if we can avoid autologous bone marrow transplantation by using the new drugs; for now the answer to this is no as Prof. Cavali explains. In follicular lymphoma, a lot of drugs are being developed but none of them stand out. The main message to treating physicians is to try and treat as little as possible and adapt treatment to the biology of the disease.
Recorded at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter